[The morbidity of adult population in the Russian Federation and its Federal Okrugs and Subjects in 2016-2022].

The population morbidity is one of leading indicators of public health. On the basis of morbidity, not only population needs in various types of medical care are determined, but also development of medical organizations network is prognosticated and effectiveness of health care system is assessed. This approach permits to adjust functioning of population medical care services in each Subject of the Russian Federation.

National Results of Revascularization for Acute Coronary Syndrome in 2023.

Aim    To analyze the results of myocardial revascularization in the Russian Federation (RF) for ACS in 2023 compared to previous years.Material and methods    The analysis included the number of cases of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), myocardial revascularization in the above-listed ACS forms, the number of fatal outcomes depending on the ACS form and the revascularization method used. The data for this analysis were obtained from the 2023 Ministry of Health of Russia monitoring in the section of revascularization in ACS and were compared with the data for the past 8 years.

Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016-2020.

Aim    To analyze the number of cases of acute coronary syndrome (ACS) [ST segment elevation myocardial infarction (STEMI), non-ST elevation acute coronary syndrome (nSTEACS)] and results of myocardial revascularization for ACS as a part of the monitoring performed by the Ministry of Health Care of Russia*. This analysis allows, on one hand, providing control of morbidity and mortality of patients with socially significant pathologies and, on the other hand, monitoring the effectivity of treatments to identify and correct their shortcomings. Time-related changes in results of myocardial revascularization performed for ACS patients in the Russian Federation in 2020 were analyzed and compared with the values of 2016-2019 based on data of the Russian Ministry of Health Care monitoring.

[Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension].

Aim: To compare in the non-blind randomised parallel study the efficiency of quadropril and amlodipine in the treatment of mild to moderate arterial hypertension.

Material And Methods: A total of 80 patients (57.6 +/- 1.

[Ramipril effects on 24 hour profile of blood pressure in patients with mild and moderate hypertension].

Aim: The study of the effects of the inhibitor of angiotensin converting enzyme ramipril (tritace) on the 24-h profile of blood pressure (BP) in patients with mild and moderate arterial hypertension.

Materials And Methods: Ramipril was given to 21 males aged 45-68 years with essential hypertension stage II (WHO criteria) with stable elevated diastolic blood pressure (95-114 mm Hg) in a single dose 2.5-10 mg/day.

[Effect of long-term monotherapy with propranolol and nifedipine on the quality of life and psychological status of patients with hypertension].

WHO criteria of quality of life and psychological status were employed in a randomized placebo-controlled cross-over trial of relevant effects induced by propranolol and nifedipine. Forty patients with essential hypertension (EH) stage I-II aged 35-60, males with diastolic pressure 96-114 mm Hg, entered the trial. Monotherapy with calcium antagonist nifedipine produced a beneficial effect on EH patients' quality of life, they became more sociable and active.

[The effect of monotherapy with nifedipine and hydrochlorothiazide on the psychological characteristics and quality of life of hypertension patients].

The study comprised 25 males with Stages I-II hypertensive disease whose age was 35 to 60 years and diastolic blood pressure was 96-114 mm Hg. After 4-week administration of placebo, two groups of treatment were randomized: (1) nifedipine (corinfar), 15-80 mg daily, and (2) hydrochlorothiazide (triampur), 25-100 mg daily, for 12 weeks with subsequent crossover: between therapy course, the patients received placebo during 4 weeks. The psychological examination was performed before the patients' inclusion into the study, at the end of placebo use, 4 and 12 weeks after monotherapy with one of the active drug, by using the "Lifestyle" questionnaire, SMOL and HPPQ.

[Differences in hemodynamic effects of the cardioselective beta-adrenoblocker acebutolol and non-selective beta-adrenoblocker propranolol in long-term antihypertensive therapy].

The cardioselective beta-adrenoblocker acebutolol used as a course therapy for 12 weeks was found to be a highly beneficial antihypertensive agent. The antihypertensive effect of the agent given in doses of 400-800 mg/day was as pronounced and prolonged as that of propranolol, 80-160 mg/day, though there is a tendency for acebutolol to show its complete or partial antihypertensive effect rather at the end of monotherapy than propranolol. At the same time the bradycardiac effect was more pronounced in propranolol therapy.